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http://dx.doi.org/10.1016/j.hkjn.201Summary Renal impairment is a common and severe complication ofmultiplemyeloma. Initial
supportive treatment, especially hydration, cessation of nephrotoxic agents, avoidance of
contrast for radiological studies, early treatment of infection, is often important in salvaging
renal function. Bisphosphonates in patients with renal failure should be used with caution and
best avoided in the initial stages, unless hypercalcemia is present. Novel criteria based on esti-
mated Glomerular Filtration Rate (GFR) measurements are recommended for treatment in such
patients and may lead to significant reversibility of renal impairment. High-dose dexamethasone
therapies arehighly active inmyelomapatientswith renal impairment. Available data support the
safety and efficacy of bortezomib-based therapies in this setting, so bortezomib with dexameth-
asone is the recommended treatment for myeloma patients with renal impairment of any grade.
A high-dose therapy with autologous stem cell transplantation can be an option for such patients;
the high-dose regimen should consist of melphalan 140 mg/m2, and the procedure should be
restricted to patients younger than 60 years of age with chemosensitive disease and a good per-
formance status.
腎臟損傷是多發性骨髓瘤的一個常見且嚴重併發症，初期的支持性療法對腎功能的拯救往往是重
要的，特別是補液、腎毒性藥物的停止、顯影劑的避免、感染的盡早治療等措施。對於腎衰竭患
者，除非已出現高鈣血症，否則應盡可能及早避免使用雙磷酸鹽類藥物。採用以 eGFR為基礎的
新標準，可能有助於腎臟損傷的顯著逆轉。對於出現腎臟損傷的骨髓瘤患者，高劑量 dexametha-
sone是高度有效的療法。目前的數據支持 bortezomib療法在這方面的安全性與功效，因此對於
出現任何等級腎臟損傷的骨髓瘤患者，bortezomib與 dexamethasone是建議的合併療法。自體
幹細胞移植的高劑量療法是另一選項，其中宜採用 melphalan 140 mg/m2，治療對象應限制於 60
歲以下、對化療敏感且功能狀況良好的病人。ternet.com.
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Table 1 International Staging System.
Stage Criteria
I Serum b2M < 3.5 mg/L
Serum albumin  3.5 g/dL
II Serum b2M < 3.5 mg/L and albumin <3.5 g/dL
or serum b2M 3.5e5.5 mg/L irrespective
of the serum albumin
III Serum b2M  5.5 mg/L
b2M Z b2-microglobulin.
Table 2 DurieeSalmon Staging System.
Stagea Criteria
I All of the following:
(1) Hb > 10 g/dL
(2) Normal calcium
(3) Skeletal survey: normal or single plasmacytoma
or osteoporosis
(4) Serum paraprotein level < 5 g/dL if IgG,
<3 g/dL if IgA
(5) Urinary light chain excretion <4 g/24 h
II Fulfilling the criteria of neither Stage I nor Stage III
III One or more of the following:
1. Hb < 8.5 g/dL
2. High calcium > 12 mg/dL
3. Skeletal survey: three or more lytic bone lesions
4. Serum paraprotein > 7 g/dL if IgG, >5 g/dL if IgA
5. Urinary light chain excretion > 12 g/24 h
Hb Z hemoglobin; Ig Z immunoglobulin.
a Stages I, II and III of the DurieeSalmon Staging System can be
divided into A or B depending on serum creatinine: A, serum
creatinine <2 mg/dL (<177 mmol/L) and B, serum creatinine
2 mg/dL (177 mmol/L).
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Multiple myeloma (MM) is characterized by a neoplastic
proliferation of plasma cells associated, in more than 95%
of cases, with the production of a single class of immuno-
globulins (IgGs) known as a monoclonal protein (M protein),
which can be either its subclass (e.g., IgG, IgA, or IgM) or its
light chain in the serum or urine (Bence Jones protein),
with IgD M protein being extremely rare.
The age-adjusted incidence rate for MM is 5.8 per
100,000 per year. It is the second most prevalent blood
cancer (10%) after non-Hodgkin’s lymphoma. It represents
approximately 1% of all cancers and 2% of all cancer deaths.
Although the peak age of onset of MM is 65e70 years,
recent statistics indicate both an increasing incidence and
an earlier age of onset.
It is more common in men and the Afro-Caribbean pop-
ulation. With the conventional treatment, median survival
is 3e4 years, which may be extended to 5e7 years or longer
with new forms of treatment using novel therapies.
Renal impairment is a common feature of MM; studies
have shown that renal impairment is associated with inferior
survival, and in particular, the presence of hypercalcemia
and light chain proteinuria are themain causes ofmyeloma in
more than 90% of cases.1 Renal failure and infection together
account for the cause of death in more than half of patients
with myeloma.2e5 At diagnosis, the serum creatinine level in
30e40% of patients with symptomatic MM is above the upper
limit of normal and in approximately 20% of patients it is
above 2mg/dL. Less than 10% of patients presentwith severe
renal failure. Renal impairment can also develop over time,
and an estimated 25e50% of patients are affected during the
course of their disease. Therapeutically, it is important to
note that the introduction of novel chemotherapy agents
such as thalidomide and bortezomib has led to improved
survival in patients with MM,6,7 and now evidence exists that
this improvement also occurs in patients with renal impair-
ment. Some studies have indicated that reversibility of renal
impairment is associated with improved survival.8e10
Thus, a proper assessment of renal function is a manda-
tory part of any initial assessment when myeloma or related
plasma cell disorders such as amyloidosis or IgGs deposition
diseases are suspected. Conversely, plasma cell disorders
are also important in the differential diagnosis of any pa-
tients presented with either acute or chronic renal failure.
Diagnostic workup
The principle of a comprehensive diagnostic workup is not
only to establish the diagnosis of myeloma, but also to
assess the extent of tissue damage from plasma cell infil-
tration and its effects on the organs affected, leading to a
proper staging (Tables 1 and 2) of the disease with a view
that chemotherapy, supportive therapy, and radiotherapy
can be initiated.
(1) The initial workup includes a complete blood count,
liver function test, bone profile (such as calcium), and
proper assessment of renal function.
(2) X-rays of the skull, axial skeleton, and proximal long
bones, collectively known as skeletal survey, areperformed. Myeloma activity sometimes appear as
“lytic lesions” (with local disappearance of normal bone
due to reabsorption) and, on the skull X-ray, as
“punched-out lesions” (pepper pot skull). However,
such lytic lesions can be observed only in conventional
plain films when more than 70% of bone trabecular is
lost. Magnetic resonance imaging is more sensitive than
plane X-ray in the detection of lytic lesions and may
supersede skeletal survey, especially when vertebral
disease is suspected. Occasionally, a computed tomo-
graphic scan is performed to measure the size of soft
tissue plasmacytomas. Bone scans are typically not of
any additional value in the workup of myeloma patients
because there is no new bone formation and lytic le-
sions are not visualized well on a bone scan.
(3) Bone marrow biopsy is usually performed to estimate the
percentage of bonemarrowoccupied byplasma cells. This
percentage is used in the diagnostic criteria for myeloma.
Flow cytometry can detect plasma cells that express IgGs
in the cytoplasm and occasionally on the cell surface;
myeloma cells are typically CD56, CD38, and CD138 posi-
tive and CD19 and CD45 negative. Cytogenetics may also
be performed in myeloma for prognostic purposes for
anomalies such as the deletion of chromosome 13, t
(4:14), or t (14:16) 11, which confer a worse prognosis.11
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measurement by protein electrophoresis and immuno-
fixation of IgA, IgG, and IgM to establish the presence
of monoclonal protein and immune paresis. It is also
essential to check the level of beta 2-microglobulin,
which provides prognostic information. The presence
of a Bence Jones protein must be sought and, if pre-
sent, a 24-hour urine quantitation for this protein is
essential. The level of monoclonal protein in the serum
(free light chain) or quantitation of the Bence Jones
protein is important in monitoring the response to
chemotherapy.
The recent introduction of a commercial immunoassay
for the measurement of free light chains in the serum
potentially offers an improvement in monitoring disease
progression and response to treatment, particularly where
the paraprotein is difficult to measure accurately by elec-
trophoresis (e.g., in light chain myeloma or where the
paraprotein level is very low). Initial research also suggests
that measurement of free light chains may also be used, in
conjunction with other markers, for assessing the risk of
progression from monoclonal gammopathy of undetermined
significance (MGUS) to MM. This serum-free light chain assay
has recently been recommended by the International
Myeloma Working Group for the screening, diagnosis,
prognosis, and monitoring of plasma cell dyscrasias.12Diagnostic criteria and classification of its subtypes
In 2003, the International Myeloma Working Group13 agreed
on the diagnostic criteria for symptomatic myeloma,
asymptomatic myeloma, and MGUS.
Clinical application of this classification has widely been
accepted as a key development in managing plasma cells
disorders, as it helps to define at what stage the clinicians
need to be considering the use of chemotherapy. Based on
this classification, most clinicians have generally accepted
that chemotherapy is needed in case of tissue damage
related to excessive plasma cells, except in cases of more
localized lytic lesions where only localized radiotherapy is
indicated. So far, early chemotherapy in the absence of any
tissue damage has not been shown to have any effect on the
prognosis.
Clinically, myeloma has been regarded as having several
subtypes; however, only symptomatic myeloma will be
discussed here, as treatment is generally not needed in
case of symptomatic myeloma or MGUS clinically, myeloma
has been regarded as having several subtypes.
Symptomatic myeloma is defined as follows: clonal
plasma cells > 10% on bone marrow biopsy or (in any quan-
tity) in biopsy from other tissues (plasmacytoma); a mono-
clonal protein (paraprotein) in either serum or urine (except
in case of true nonsecretory myeloma).
Evidence of end-organ damage felt related to the plasma
cell disorder (related organ or tissue impairment, commonly
referred to by the acronym “CRAB”): hypercalcemia (cor-
rected calcium > 2.75 mmol/L); renal insufficiency attrib-
utable to myeloma; anemia (hemoglobin < 10 g/dL); and
bone lesions (lytic lesions or osteoporosis with compression
fractures).Note: Recurrent infections alone in a patient who has
none of the CRAB features are not sufficient to make the
diagnosis of myeloma. Patients who lack CRAB features but
have evidence of amyloidosis should be considered to have
amyloidosis and not myeloma. CRAB-like abnormalities are
common with numerous diseases, and it is imperative that
these abnormalities are felt to be attributable directly to
the related plasma cell disorder and every attempt is made
to rule out other underlying causes of anemia, renal failure,
etc.
Staging
International Staging System
The International Staging System (ISS) for myeloma was
published by the International Myeloma Working Group.14
Note that the ISS should be used only in patients who
meet diagnostic criteria for myeloma. Patients with MGUS
and asymptomatic myeloma who have renal dysfunction
from unrelated causes such as diabetes or hypertension
may have elevated b2M levels just from the renal
dysfunction and cannot be considered as patients with
Stage III myeloma. This is one of the main drawbacks of the
ISS. Unlike staging systems used in other cancers, it does
not really quantify tumor burden or extent. It is more of a
prognostic index than a true staging system. For this
reason, it is recommended that the ISS be used along with
the DurieeSalmon Staging System (see below).
DurieeSalmon Staging System
First published in 1975,15 the DurieeSalmon Staging System
is still in use.
Pathophysiology of renal impairment in
myeloma
Renal dysfunction in MM results primarily from the toxic
effects of monoclonal light chains on the kidneys (light-
chain-only myeloma accounts for about 15% of cases of all
myeloma), in addition to other contributing factors such as
dehydration, hypercalcemia, hyperuricemia, concurrent
use of nephrotoxic drugs (nonsteroidal anti-inflammatory
drugs, antibiotics, contrast media, etc.), and, rarely,
myeloma cell infiltration or hyperviscosity due to high
monoclonal protein level, especially of the IgA subclass.16
In more than 90% of cases of light-chain myeloma with
renal impairment, renal biopsy shows the characteristic
cast nephropathy with tubular atrophy and evidence of
tubular interstitial fibrosis.17
In other cases, evidence of light-chain glomerulopathy
with deposition of Igs, in either amyloid or nonamyloid
form, may exist. In both glomerulopathies, the develop-
ment of nonselective proteinuria is the dominant syn-
drome. Amyloid deposits predominate within the glomeruli
and give a positive Congo red staining. In monoclonal IgGs
deposition disease (MIDD), the glomerular deposits of IgGs
light or heavy chains are nonfibrillar and Congo red
negative.
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impairment is multifactorial, at least in a subset of patients
with myeloma. These factors must be identified at diag-
nosis, as management of these factors will be essential in
the reversibility of the renal impairment.
The need of a renal biopsy is not part of the standard
workup for a patient with myeloma presenting with renal
impairment. If the patient has proteinuria consisting mainly
of light chains, a renal biopsy is not necessary. The pres-
ence of nonselective proteinuria or significant albuminuria
may support the suspicion of amyloidosis or MIDD; there-
fore, in patients with nephrotic syndrome with or without
renal failure, a renal biopsy may be necessary to search
for amyloid, MIDD, or unrelated glomerulopathy such as
glomerulonephritis or diabetes nephritis.
Management of myeloma patients with renal
impairment
Until recently, the median survival time of MM patients with
renal insufficiency was less than 1 year,3e5,8 and patients
requiring dialysis had a particularly poor prognosis. How-
ever, the prognosis for these patients has improved
recently due to the availability of more effective treat-
ments for myeloma and improvement in supportive care.
Supportive care
Adequate hydration, urine alkalization, and management of
hypercalcemia are important supportive measures for the
management of myeloma patients with acute renal failure,
and may restore renal function in some patients.
For the treatment of hypercalcemia in myeloma patients
with renal impairment, adequate hydration is necessary.
Bisphosphonates have to be given according to the guide-
lines for estimated GFR (eGFR); intravenous bisphospho-
nates should be retained in patients with GFR under 30 mL/
min. For zoledronic acid, dose reduction has been recom-
mended for patients with GFR between 30 mL/min and
60 mL/min.
Drugs that may contribute to renal damage, such as
nonsteroidal anti-inflammatory drugs, intravenous contrast
dyes, aminoglycosides, or other antibiotics that have sig-
nificant renal excretion, should be avoided. If a myeloma
patient with renal failure needs intravenous contrast media
for diagnostic purposes, dialysis immediately after the
procedure is recommended.
Mechanical approaches
Mechanical means of treating MM patients with renal
impairment include long-term dialysis, plasmapheresis, and
novel dialysis filters for the removal of free light chains.
Long-term dialysis is a worthwhile supportive measure for
patients with MM and end-stage renal disease. If patients
with dialysis-dependent renal insufficiency who die within
the first 2 months of therapy (approximately 30% of the
total) are excluded, then long-term dialysis in combination
with conventional antimyeloma therapy can lead to a me-
dian survival time of approximately 2 years.16 The role ofplasmapheresis has been evaluated in the context of pro-
spective clinical trials, and no clear benefit was detected.18
The removal of free light chains with dialysis is another
approach. However, the removal of such chains by a
conventional dialysis membrane is restricted by their mo-
lecular weight cutoffs. A new high-cutoff hemodialysis
membrane with molecular cutoffs closer to that of the
native kidney (65 kDa) seemed to remove circulating light
chains more efficiently and has recently been tested in the
MM setting, with initial encouraging results.19
Chemotherapy
Bortezomib (a proteasome inhibitor)-containing
chemotherapy regimen
Bortezomib is a novel antineoplastic agent and has been
tested extensively in hematological malignancies, espe-
cially MM including MM in renal failure. It is cleared rapidly
following intravenous administration, with peak concen-
trations being reached at about 30 minutes; is not excreted
via kidneys; and, in animal models, has demonstrated sig-
nificant antimyeloma activity.
Now, bortezomib has been accepted as safe and can
be administered effectively at the full approved dose
and schedule in patients with impaired renal function; in
some cases, it can reverse renal failure and improve
survival.20e23 This has now replaced the traditional treat-
ment of MM in renal failure with an infusion of vincristine/
adriamycin/dexamethaxone.
In a subanalysis of the SUMMIT (Study of Uncontrolled
Multiple Myeloma Managed with Proteasome Inhibition
Therapy) and the CREST (Clinical Response and Efficacy
Study of Bortezomib in the Treatment of Relapsing Multiple
Myeloma) phase 2 studies, three of 10 (30%) patients with a
creatinine clearance (CRCL) of 30 mL/min and below
responded to treatment, compared with a 45% overall
response rate in patients with baseline CRCL of above
80 mL/min. Discontinuation rates and adverse-event pro-
files were similar between patients with CRCL above
80 mL/min and those with CRCL 50 mL/min and below.
The standard dose for bortezomib is 1.3 mg/m2 intra-
venous bolus injections twice weekly for 2 weeks in a
3-week cycle; the total number of cycles varies between 4
and 8, depending on response and tolerance. The main side
effects of this will be peripheral neuropathy and reversible
thrombocytopenia. In the presence of significant neuropa-
thy, dose reduction to 1.0 mg/m2 or even weekly. More
recently, this drug has been licensed for subcutaneous in-
jection, which seems to have less neuropathic side effects
(UK Myeloma Forum, personal communication).
The efficacy of combination therapy using bortezomib,
melphalan, and prednisolone had also been demonstrated
in the updated international phase III VISTA trial with longer
overall survival across all subgroups defined by baseline
characteristics including creatinine clearance.24
Immunomodulatory drug-based regimens
Thalidomide is the first immunomodulatory drug with
proven activity in MM. Thalidomide pharmacokinetics are
not affected by renal impairment, and thus no dose
reduction is required in MM patients with renal impairment.
66 P. ChuThe standard dose of thalidomide is between 100 mg and
200 mg daily depending on the tolerance of side effects,
especially marrow suppression.
In a single-center case series (N Z 20) of patients with
relapsed/refractory MM and renal impairment (defined as
serum creatinine above 2 mg/dL), treatment with thalido-
mide alone (n Z 8) or thalidomide plus dexamethasone
(n Z 12) resulted in 45% partial response and 30% minimal
response. The median duration of response was 7 months,
whereas 12/15 responding patients had improved renal
function, defined as serum creatinine less than 2 mg/dL.25
Lenalidomide is another effective agent for the man-
agement of MM. It is excreted mainly by the kidneys,
through both glomerular filtration and active tubular
secretion. It is therefore not regarded as the front-line
therapy for patients with myeloma presenting with renal
failure, and, if used, dose reduction will be necessary to
avoid toxicities. Data on its efficacy in renal failure are
therefore very limited.26
Hematopoietic stem cell transplant
Autologous stem cell transplantation should be considered
as a consolidation therapy after achieving a plateau phase
with combination chemotherapy in younger patients (less
than 65 years of age); the response rate can be as high as 80%
with survival improved up to 18 months. The use of ASCT in
patients with myeloma, renal insufficiency (serum creati-
ninemore than 2mg/dL), and end stage renal disease (ESRD)
has also resulted in similar response rates and outcomes;
however, the transplant-related mortality rate was higher,
up to 13%.27e29 In patients who havemyeloma and are new to
dialysis, successful use of ASCT has led to the recovery of
renal function and discontinuation of dialysis in up to 24% of
cases.30,31 The role of allogeneic stem cell transplant using a
human leucocyte antigen (HLA)-compatible donor is still not
clear and is associated with high transplant mortality. It
should be considered only in much younger patients with an
HLA-compatible sibling, preferably in the context of a large
clinical trial.
Conclusions
Renal impairment is a common and severe complication of
MM. Initial supportive treatment, especially hydration,
cessation of nephrotoxic agents, avoidance of contrast for
radiological studies, and early treatment of infection, are
often important in salvaging renal function. Bisphospho-
nates in patients with renal failure should be used with
caution and best avoided in the initial stages, unless hy-
percalcemia is present. Novel criteria based on eGFR
measurements are recommended for the treatment of such
patients and may lead to significant reversibility of renal
impairment. High-dose dexamethasone therapies are highly
active in myeloma patients with renal impairment. Avail-
able data support the safety and efficacy of bortezomib-
based therapies in this setting, so bortezomib with dexa-
methasone is the recommended treatment for myeloma
patients with renal impairment of any grade. Lenalidomide
is a feasible and effective treatment option for patients
with mild to moderate renal impairment, but it should beadministered at the recommended reduced dose based on
renal function. Thalidomide is also an option for patients
with severe renal impairment, although the data on this are
less extensive. Combinations of bortezomib and immuno-
modulatory drugs along with high-dose dexamethasone
have also shown superior antimyeloma activity to the
traditional vincristine/adriamycin/dexamethaxone infu-
sion, although no comparative studies have been performed
specifically in patients with renal impairment. High-dose
therapy with ASCT can be an option for such patients; the
high-dose regimen should consist of melphalan 140 mg/m2,
and the procedure should be restricted to patients younger
than 65 years of age with chemosensitive disease and a
good performance status.References
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